Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study

Overview

Journal Turk J Haematol

Specialty Hematology

Date 2019 Jul 25

PMID 31337191

Citations 4

Authors

Viktoria Plamenova Varbanova

Snejina Mihailova

Elissaveta Naumova

Anastasiya Petrova Mihaylova

Affiliations

Soon will be listed here.

Abstract

Objective: Natural killers (NK) cell function is mainly controlled by the expression of killer immunoglobulin-like receptors (KIRs) and their ligation with the corresponding ligands. The objective of this study was to investigate the putative association of KIRs, HLA class I ligands, and KIR/ligand combinations with rates of development of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

Materials And Methods: The KIR/HLA I genotypes of 82 patients with leukemia (ALL, n=52; AML, n=17; and CML, n=13) were determined by PCR-SSP method and compared with genotypes of healthy controls (n=126).

Results: KIR genotype frequency differed significantly between myelogenous leukemia patients and healthy controls for KIR2DL5A (17.6% vs. 47.7%, p=0.02), KIR3DS1 (17.6% vs. 47.6%, p=0.02), and KIR2DS4*001 (36.6% vs. 20.2%, p=0.017). The incidence of homozygous HLA-BBw4 (31.0% vs. 12.5%, p=0.042) and HLA-Bw4Thr80 Thr80 (13.0% vs. 1.2%, p=0.01) was significantly elevated in myeloid leukemia patients compared to healthy controls. KIR/HLA class I ligand profile KIR3DS1(+)/L (-) was decreased and KIR3DL2(+)/HLA-A3/11(-) was increased among myeloid leukemia cases compared to controls.

Conclusion: These data suggest that the activity of NK cells as determined by inherited KIR/HLA class I ligand polymorphisms influences the susceptibility to myelogenous leukemia, but not to lymphoblastic leukemia. Additionally, the KIR genotype characterized by the absence of the inhibitory KIR2DL2 and the activating KIR2DS2 and KIR2DS3 (ID2) was found at a lower frequency in patients compared to controls, which confirmed the need for complex analysis based on all possible KIR/HLA class I ligand polymorphism combinations.

Citing Articles

Association of killer immunoglobulin-like receptor genotypes and haplotypes with acute lymphoblastic leukemia risk.

Al-Tamimi J, Alomar S, Aljuaimlani A, Mansour L Innate Immun. 2025; 31:17534259251314774.

PMID: 39828905 PMC: 11774482. DOI: 10.1177/17534259251314774.

Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in Iranian patients.

Mirzazadeh S, Bemani P, Halimi H, Sanaee M, Karami N, Ramzi M Sci Rep. 2023; 13(1):11456.

PMID: 37454198 PMC: 10349836. DOI: 10.1038/s41598-023-38479-x.

NK cell defects: implication in acute myeloid leukemia.

DSilva S, Singh M, Pinto A Front Immunol. 2023; 14:1112059.

PMID: 37228595 PMC: 10203541. DOI: 10.3389/fimmu.2023.1112059.

Frequency of HLA alleles and KIR Ligands in Acute Myeloid Leukemia in Indian Cohort.

DSilva S, Bodade A, Kadam S, Tambe M, Dhanda S, Bagal B Indian J Hematol Blood Transfus. 2023; 39(1):50-56.

PMID: 36699439 PMC: 9868221. DOI: 10.1007/s12288-022-01550-0.

[Effect of KIR/HLA receptor-ligand mode on prognosis of single unrelated cord blood transplantation in patients with hematological malignancies].

Fang T, Zhu X, Tang B, Liu H, Wan X, Song K Zhonghua Xue Ye Xue Za Zhi. 2020; 41(3):204-209.

PMID: 32311889 PMC: 7357922. DOI: 10.3760/cma.j.issn.0253-2727.2020.03.004.

References

La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R . The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. J Hematol Oncol. 2016; 9:26. PMC: 4793496. DOI: 10.1186/s13045-016-0255-4. View

WINTER C, Long E . A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 1997; 158(9):4026-8. View

Vales-Gomez M, Reyburn H, Mandelboim M, Strominger J . Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity. 1998; 9(3):337-44. DOI: 10.1016/s1074-7613(00)80616-0. View

Besson C, Roetynck S, Williams F, Orsi L, Amiel C, Lependeven C . Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study. PLoS One. 2007; 2(5):e406. PMC: 1853236. DOI: 10.1371/journal.pone.0000406. View

David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K . Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol. 2013; 191(9):4778-88. DOI: 10.4049/jimmunol.1301580. View

Augusto D . The Impact of KIR Polymorphism on the Risk of Developing Cancer: Not as Strong as Imagined?. Front Genet. 2016; 7:121. PMC: 4923111. DOI: 10.3389/fgene.2016.00121. View

Demanet C, Mulder A, Deneys V, Worsham M, Maes P, Claas F . Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. Blood. 2004; 103(8):3122-30. DOI: 10.1182/blood-2003-07-2500. View

Middleton D, Diler A, Meenagh A, Sleator C, Gourraud P . Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 2009; 73(6):553-60. DOI: 10.1111/j.1399-0039.2009.01235.x. View

Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G . Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003; 102(3):814-9. DOI: 10.1182/blood-2003-01-0091. View

10.

Zhang Y, Wang B, Ye S, Liu S, Liu M, Shen C . Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease. Leuk Res. 2009; 34(1):55-8. DOI: 10.1016/j.leukres.2009.04.022. View

11.

Gumperz J, Litwin V, Phillips J, Lanier L, Parham P . The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995; 181(3):1133-44. PMC: 2191933. DOI: 10.1084/jem.181.3.1133. View

12.

de Smith A, Walsh K, Ladner M, Zhang S, Xiao C, Cohen F . The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia. Blood. 2014; 123(16):2497-503. PMC: 3990912. DOI: 10.1182/blood-2013-11-540625. View

13.

Misra M, Prakash S, Roy Moulik N, Kumar A, Agrawal S . Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians. Hum Immunol. 2015; 77(1):41-46. DOI: 10.1016/j.humimm.2015.10.009. View

14.

Sullivan E, Jeha S, Guolian Kang , Cheng C, Rooney B, Holladay M . NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 2014; 20(23):5986-94. PMC: 4252745. DOI: 10.1158/1078-0432.CCR-14-0479. View

15.

Colonna M, Samaridis J . Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science. 1995; 268(5209):405-8. DOI: 10.1126/science.7716543. View

16.

Chewning J, Gudme C, Hsu K, Selvakumar A, Dupont B . KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007; 179(2):854-68. DOI: 10.4049/jimmunol.179.2.854. View

17.

Karabon L, Jedynak A, Giebel S, Wolowiec D, Kielbinski M, Woszczyk D . KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens. 2011; 78(2):129-38. DOI: 10.1111/j.1399-0039.2011.01721.x. View

18.

Verheyden S, Schots R, Duquet W, Demanet C . A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005; 19(8):1446-51. DOI: 10.1038/sj.leu.2403839. View

19.

Venstrom J, Gooley T, Spellman S, Pring J, Malkki M, Dupont B . Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010; 115(15):3162-5. PMC: 2858471. DOI: 10.1182/blood-2009-08-236943. View

20.

Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K . Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999; 94(1):333-9. View